Methods of making a nucleic acid sequencing library and compositions thereof
The method of controlled nucleic acid base tail attachment in nucleic acid sequencing library construction addresses the challenges of limited cfDNA samples by increasing library complexity and yield, improving sequencing sensitivity and diagnostic capabilities.
Patent Information
- Application Number
- PCT/US2024/028161
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for constructing nucleic acid sequencing libraries from cell-free DNA (cfDNA) samples, particularly those with limited amounts, often result in compromised library complexity and yield, leading to insufficient sample material and increased risk of false negatives in diagnostic testing.
A method involving controlled nucleic acid base tail attachment to the 3' ends of nucleic acid molecules within a reaction time of less than 30 minutes, including blunting ends, attaching a phosphate to 5' ends, and attaching sequencing adaptors, which increases library complexity and yield.
This approach enhances sequencing sensitivity, allows for lower sample input requirements, and increases the efficiency of downstream information acquisition, enabling analysis of previously excluded patient samples by maintaining or increasing the number of nucleic acid molecules during library construction.
Smart Images

Figure 000030 
Figure 000031 
Figure 000032
Abstract
Description
METHODS OF MAKING A NUCLEIC ACID SEQUENCING LIBRARY ANDCOMPOSITIONS THEREOFCROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the priority benefit of U.S. Provisional Patent Application No. 63 / 464,909, filed May 8, 2023, the entire contents of which are incorporated herein by reference for all purposes.FIELD OF THE INVENTION
[0002] Disclosed herein is a method of constructing a nucleic acid sequencing library and the sequencing library made according to said methods.BACKGROUND
[0003] Cell-free DNA (cfDNA) molecules are free-floating double stranded DNA molecules (dsDNA or duplex DNA) found in the blood stream, typically as the result of cell apoptosis or necrosis, particularly in the context of disease, such as cancer. These cfDNA molecules can include both circulating tumor DNA (ctDNA) and non-tumor DNA; the ctDNA in particular can be valuable for cancer diagnostic purposes. These degraded linear DNA fragments are often approximately 20-500 base pairs in length, and often isolated in low concentrations from body fluids and tissue, such as blood, plasma, saliva, or serum.
[0004] In some instances, particularly with early-stage cancer samples, the amount of cfDNA, including ctDNA, in the sample is limited. When the sample is limited such as with a cfDNA sample collected from a blood draw, the library complexity and yield can be compromised such that there can be insufficient sample material for diagnostic testing as well as increased risk of false negatives, both of which impede potentially lifesaving patient care by undermining the efficacy of relevant diagnostic tests. Current methods to address these problems include increasing adaptor concentration, decreasing the number of solid-phase reversible immobilization (SPRI) bead nucleic acid purification steps, and modulating SPRI conditions during nucleic acid purification. However, these methods prove insufficient to address the problem at hand due to issues such as adaptor dimerization or clustering, reduction in nucleic acid purity, and loss of nucleic acid fragments below 150-200bp.Furthermore, these methods fail to address any issues introduced during the earlier stages of library preparation that may decrease library complexity or yield.
[0005] Thus, it becomes increasingly important to identify novel ways to increase the number of nucleic acid molecules (e.g., cfDNA molecules) that are retained in library construction in order to increase library yield and the number of unique molecules that are sequenced (i.e., library complexity). Maintaining or increasing the number of nucleic acid molecules during library construction has multiple benefits, including increasing library complexity and decreasing the necessary amount of input nucleic acid mass. These benefits reduce the risk of false negatives, conserve sample in cases where the available cfDNA concentration is particularly limited, and increase the likelihood that a patient’s sample will meet the threshold for lifesaving diagnostic testing.SUMMARY OF THE INVENTION
[0006] Described herein is a method of constructing a nucleic acid library, for example from a DNA sample (such as cfDNA), that includes attaching a nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules. The time of the nucleic acid base tail attachment reaction is controlled, however, so that the reaction time is less than 30 minutes (for example 5 minutes or less, or about 1 to about 5 minutes). Controlling the time of the nucleic acid base tail attachment reaction to less than 30 minutes provides a nucleic acid library that displays increased library complexity compared to a nucleic acid library constructed using a nucleic acid base tailing reaction lasting 30 minutes or longer. The increased complexity of the nucleic acid library in turn provides increased sequencing sensitivity.
[0007] The method described herein increases library yield (i.e., the number of nucleic acid molecules from a sample that are present in the resulting nucleic acid library) and library complexity (i.e., the number of unique molecules in the nucleic acid library) compared to other methods of library construction that rely on longer nucleic acid base tailing reaction times. In fact, the standard reaction time manufacture protocols suggest a 30-minute reaction time. Increasing library complexity can allow for a lower amount of sample to be collected from an individual and / or a lower amount of nucleic acid sample (such as cfDNA) to be used as input in a reaction, which leaves a greater amount of the nucleic acid (such as cfDNA) sample available for use in additional reactions or experiments. As a result, the efficiency of downstream information acquisition (e.g., information related to the onset, progression, diagnosis, treatment, etc. of various diseases, (e.g., cancers)) is increased, and patient samples that would have been excluded due to low nucleic acid yield can now be analyzed. The loss of information due to low yield or low library complexity is an obstacle both to theunderstanding of disease processes, to the diagnostic capabilities and to the utilization of this information for the improvement of human health (e.g., early detection of diseases, the association to treatment efficacies, etc.).
[0008] In one aspect is provided a method of constructing a nucleic acid library, comprising: blunting ends of a plurality of nucleic acid molecules; attaching a phosphate to 5' ends of the plurality of nucleic acid molecules; attaching a nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules in a reaction that proceeds for less than 30 minutes; and attaching one or more sequencing adaptors to the plurality of nucleic acid molecules. Also described herein is a sequencing library made according to any of the methods described herein.
[0009] In some embodiments, blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs at about 15°C to about 25°C.
[0010] In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 25 minutes or less. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 1 minute to about 25 minutes. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 15 minutes or less. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 10 minutes or less. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes to about 15 minutes. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 1 minute to about 5 minutes. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 5 minutes or less. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds at about 37°C to about 72°C. In some embodiments, the nucleic acid base tail is a deoxy adenosine tail. In some embodiments, the nucleic acid base tail is a deoxythymidine tail.
[0011] In some embodiments, attaching the one or more sequencing adaptors to the plurality of nucleic acid molecules comprises ligating the one or more sequencing adaptors to the plurality of nucleic acid molecules. In some embodiments, attaching the one or moresequencing adaptors to the plurality of nucleic acid molecules further comprises incubating the plurality of nucleic acid molecules ligated to the one or more sequencing adaptors with a uracil- specific excision reagent. In some embodiments, attaching one or more sequencing adaptors to the plurality of nucleic acid molecules comprises ligating the one or more sequencing adaptors to the plurality of nucleic acid molecules by a ligase.
[0012] In some embodiments, blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences. In some embodiments, blunting the ends of the plurality of nucleic acid molecules comprises filling in underhang sequences. In some embodiments, blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences and filling in underhang sequences in separate reactions. In some embodiments, blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences and filling in underhang sequences in the same reaction.
[0013] In some embodiments, blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs in the same reaction. In some embodiments, blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs in separate reactions.
[0014] In some embodiments, blunting the ends of the plurality of nucleic acid molecules, attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and attaching the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules occur in the same reaction. In some embodiments, (i) blunting the ends of the plurality of nucleic acid molecules, (ii) attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and (iii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in separate reactions. In some embodiments, (i) blunting the ends of the plurality of nucleic acid molecules and (ii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in the same reaction. In some embodiments, (i) blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and (ii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in separate reactions. In some embodiments, the reactions are separated by a nucleic acid purification process.
[0015] In some embodiments, the plurality of nucleic acid molecules comprises 1 pg or less of the nucleic acid molecules. In some embodiments, the plurality of nucleic acid molecules comprises 60 ng or less of the nucleic acid molecules. In some embodiments, the plurality of nucleic acid molecules comprises about 5 ng to 60 ng of the plurality of nucleic acidmolecules. In some embodiments, the plurality of nucleic acid molecules comprises about 5 ng to about 30 ng of the plurality of nucleic acid molecules.
[0016] In some embodiments, the plurality of nucleic acid molecules is obtained from a liquid biopsy sample or a tissue sample. In some embodiments, the liquid biopsy sample comprises blood, plasma, buffy coat, cerebrospinal fluid, sputum, stool, urine, or saliva. In some embodiments, the liquid biopsy sample comprises cell-free DNA. In some embodiments, the cell-free DNA comprises circulating tumor DNA (ctDNA). In some embodiments, the tissue sample comprises fresh frozen tissue, FFPE tissue, PBMCs, tumor biopsy, organ biopsy, bone marrow aspirate, cell lines, or hair follicles.BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Various aspects of the disclosed methods, devices, and systems are set forth with particularity in the appended claims. A better understanding of the features and advantages of the disclosed methods, devices, and systems will be obtained by reference to the following detailed description of illustrative embodiments and the accompanying drawings, of which:
[0018] FIG. 1A shows an exemplary process for making a DNA library from a plurality of nucleic acid molecules (e.g., dsDNA duplex molecules), according to some embodiments.
[0019] FIG. IB shows an exemplary embodiment of the process for making a DNA library from a plurality of nucleic acid molecules (e.g., dsDNA duplex molecules) shown in FIG.1A.
[0020] FIG. 2A shows an exemplary plot of the efficiency of an exemplary commercially available DNA library preparation kit protocol to generate fully ligated DNA products using synthetic dsDNA constructs. Fully ligated DNA products were quantified based on normalized sample intensity (fluorescence units).
[0021] FIG. 2B shows the mean quantification of the exemplary commercially available DNA library preparation kit protocol efficiency. FIG. 2B compares the protocol efficiency using the standard 30min tailing incubation compared to 5 min, 15 min, 45 min, and 60 min tailing incubations.
[0022] FIG. 3 shows the fraction of synthetic dsDNA product that is fully ligated when the tailing reaction is incubated for 1 min, 2 min, 3 min, 4 min, 5 min, 15 min, 30 min, 45 min, or 60 min. A 30 min incubation is the standard operating procedure as per the exemplary commercially available protocol. Quantification was performed using the TapeStation D1000.
[0023] FIG. 4A shows the increase in pre-PCR quantification of cfDNA sample yield from a healthy human donor of fully ligated dsDNA product at 5 min tailing incubation versus 30 min tailing incubation using 5 ng, 10 ng, 20 ng, and 30 ng of input dsDNA. Quantification was performed using the TapeStation D1000.
[0024] FIG. 4B shows the median exon coverage to quantify the unique dsDNA molecule coverage of cfDNA sample from a healthy human donor. FIG. 4B compares the unique coverage in the generated cfDNA library between 5 min tailing incubation and 30 min tailing incubation using 5 ng, 8 ng, 10 ng, 20 ng, and 30 ng of input dsDNA. Quantification was performed using targeted sequencing.
[0025] FIG. 5A shows the unique target dropout rate on a per-target level at 5 min tailing incubation compared to 30 min tailing incubation using 5 ng cfDNA sample input.
[0026] FIG. 5B shows the unique target dropout rate on a per-target level at 5 min tailing incubation compared to 30 min tailing incubation using 8 ng cfDNA sample input.
[0027] FIG. 5C shows the unique target dropout rate on a per-target level at 5 min tailing incubation compared to 30 min tailing incubation using 15 ng cfDNA sample input.
[0028] FIG. 5D shows the unique target dropout rate on a per-target level at 5 min tailing incubation compared to 30 min tailing incubation using 30 ng cfDNA sample input.
[0029] FIG. 6A shows the normalized coverage of GC content to assess for GC content bias at 5 min tailing incubation compared to 30 min tailing incubation using 5 ng cfDNA sample input.
[0030] FIG. 6B shows the normalized coverage of GC content to assess for GC content bias at 5 min tailing incubation compared to 30 min tailing incubation using 8 ng cfDNA sample input.
[0031] FIG. 6C shows the normalized coverage of GC content to assess for GC content bias at 5 min tailing incubation compared to 30 min tailing incubation using 15 ng cfDNA sample input.DETAILED DESCRIPTION
[0032] Described herein is a method of constructing a nucleic acid library, for example from a DNA sample (such as cfDNA), that includes attaching a nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules. The time of the nucleic acid base tail attachment reaction is controlled, however, so that the reaction time is less than 30 minutes (for example 5 minutes or less, or about 1 to about 5 minutes). Controlling the time of the nucleic acid base tail attachment reaction to less than 30 minutes provides a nucleic acid library thatdisplays increased library complexity compared to a nucleic acid library constructed using a nucleic acid base tailing reaction lasting 30 minutes or longer. The increased complexity of the nucleic acid library in turn provides increased sequencing sensitivity.
[0033] The method described herein increases library yield (i.e., the number of nucleic acid molecules from a sample that are present in the resulting nucleic acid library) and library complexity (i.e., the number of unique molecules in the nucleic acid library) compared to other methods of library construction that rely on longer nucleic acid base tailing reaction times. In fact, the standard reaction time manufacture protocols suggest a 30-minute reaction time. Increasing library complexity can allow for a lower amount of sample to be collected from an individual and / or a lower amount of nucleic acid sample (such as cfDNA) to be used as input in a reaction, which leaves a greater amount of the nucleic acid sample (such as cfDNA) available for use in additional reactions or experiments. As a result, the efficiency of downstream information acquisition (e.g., information related to the onset, progression, diagnosis, treatment, etc. of various diseases, (e.g., cancers)) is increased, and patient samples that would have been excluded due to low nucleic acid yield can now be analyzed. The loss of information due to low yield or low library complexity is an obstacle both to the understanding of disease processes, to the diagnostic capabilities and to the utilization of this information for the improvement of human health (e.g., early detection of diseases, the association to treatment efficacies, etc.).
[0034] The method of constructing a nucleic acid library described herein includes the following steps: blunting ends of a plurality of nucleic acid molecules; attaching a phosphate to 5' ends of the plurality of nucleic acid molecules; attaching a nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules in a reaction that proceeds for less than 30 minutes; and attaching one or more sequencing adaptors to the plurality of nucleic acid molecules. These steps can be performed such that two or more, or all of the steps, are performed in the same or in separate reactions, or in step-wise reactions. Also provided herein is a nucleic acid library that is constructed according to the method described herein. In some cases, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 25 minutes or less, for example for 15 minutes or less, for 10 minutes or less, or for 5 minutes or less. For example, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules can proceed for about 1 minute to about 25 minutes, such as for about 5 minutes to about 15 minutes, or for about 1 minute to about 5 minutes. As described herein, the reaction thatattaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules can proceed for about 5 minutes.Definitions
[0035] Unless otherwise defined, all of the technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art in the field to which this disclosure belongs.
[0036] As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Any reference to “or” herein is intended to encompass “and / or” unless otherwise stated.
[0037] ‘ ‘About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.
[0038] As used herein, the terms “comprising” (and any form or variant of comprising, such as “comprise” and “comprises”), “having” (and any form or variant of having, such as “have” and “has”), “including” (and any form or variant of including, such as “includes” and “include”), or “containing” (and any form or variant of containing, such as “contains” and “contain”), are inclusive or open-ended and do not exclude additional, un-recited additives, components, integers, elements, or method steps.
[0039] As used herein, the terms “individual,” “patient,” or “subject” are used interchangeably and refer to any single animal, e.g., a mammal (including such non-human animals as, for example, dogs, cats, horses, rabbits, zoo animals, cows, pigs, sheep, and non- human primates) for which treatment is desired. In particular embodiments, the individual, patient, or subject herein is a human.
[0040] As used herein, the term “blunting” refers to any process or reaction causing a loss or a filling in of an overhang at one or both ends of a nucleic acid molecule. Examples of reactions that can blunt the ends of nucleic acid molecules include adding nucleotides to the complementary strand along the length of the overhang and / or removing (e.g., cleaving) unpaired nucleotides in the overhang. Blunting encompasses any process or reaction wherein the nucleic acid molecule having the loss or filling in of the overhang is a final product or is an intermediate to a subsequent product. That is, an end of a nucleic acid molecule may be blunted by a reaction that subsequently forms a new overhang at the blunted end during the course of the same reaction. For example, an enzyme (e.g., a DNA polymerase) can blunt a 3'end of a nucleic acid molecule and subsequently attach a nucleic acid tail to the 3' end. In some instances, blunting can occur in multiple reactions, for example as stepwise (e.g., sequential) reactions or individual reactions separated by nucleic acid purification.
[0041] When a range of values is provided, it is to be understood that each intervening value between the upper and lower limit of that range, and any other stated or intervening value in that states range, is encompassed within the scope of the present disclosure. Where the stated range includes upper or lower limits, ranges excluding either of those included limits are also included in the present disclosure.
[0042] The section headings used herein are for organization purposes only and are not to be construed as limiting the subject matter described. The description is presented to enable one of ordinary skill in the art to make and use the invention and is provided in the context of a patent application and its requirements. Various modifications to the described embodiments will be readily apparent to those persons skilled in the art and the generic principles herein may be applied to other embodiments. Thus, the present invention is not intended to be limited to the embodiment shown but is to be accorded the widest scope consistent with the principles and features described herein.
[0043] FIGS. 1A-1B illustrate the process according to various embodiments. In the exemplary process, some blocks are, optionally, combined, the order of some blocks is, optionally, changed, and some blocks are, optionally, omitted. In some examples, additional steps may be performed in combination with the exemplary processes. Accordingly, the operations as illustrated (and described in greater detail below) are exemplary by nature and, as such, should not be viewed as limiting.
[0044] The disclosures of all publications, patents, and patent applications referred to herein are each hereby incorporated by reference in their entireties. To the extent that any reference incorporated by reference conflicts with the instant disclosure, the instant disclosure shall control.Method of Constructing a Nucleic Acid Library
[0045] Provided herein is a method of constructing a nucleic acid library (e.g., a DNA library from cfDNA molecules), comprising the following steps that may be performed blunting ends of a plurality of nucleic acid molecules; attaching a phosphate to 5' ends of the plurality of nucleic acid molecules; attaching a deoxy adenosine tail to 3' ends of the plurality of nucleic acid molecules in a reaction that proceeds for less than 30 minutes; and attaching one or more sequencing adaptors to the plurality of nucleic acid molecules. Certain embodimentsare described in reference to a plurality of nucleic acid molecules (e.g., a plurality of cfDNA molecules), but the methods may be applied for the construction of a nucleic acid library where a plurality of RNA or DNA molecules, such as duplex or double stranded molecules, which may have different topologies, may be constructed, and / or may be analyzed in parallel.
[0046] The methods described herein require a plurality of nucleic acid molecules as a starting or input material, such as nucleic acid molecules derived from a sample, e.g., any sample described herein. In some embodiments, the nucleic acid molecules are double stranded molecules. In some embodiments, the nucleic acid molecules are single stranded molecules. In some embodiments, the nucleic acid molecules are DNA molecules. In some embodiments, the nucleic acid molecules are RNA molecules. In some embodiments, the RNA molecules can be reverse transcribed into complementary DNA (cDNA) molecules. In some embodiments, the complementary DNA molecules can be amplified to create a paired complementary strand, e.g., to create a double stranded cDNA molecule. Methods of amplification can include, for example, a polymerase chain reaction (PCR) amplification technique or a non-PCR amplification technique, such as an isothermal amplification technique.
[0047] As shown in FIG. IB, a plurality of nucleic acid molecules, i.e., double- stranded nucleic acid molecules, can comprise any combination of jagged ends, blunted ends, nicks, gaps, overhangs, and underhangs. The plurality of nucleic acid molecules can include a plurality of nucleic acid topologies. In some cases, nicks, gaps, overhangs, and / or underhangs are fixed in the process of creating a nucleic acid library using the methods as described herein. For example, wherein a DNA polymerase may be utilized in any of the processes described below, nicks, gaps, overhangs, and / or underhangs may be filled in or otherwise corrected.
[0048] In some instances, the starting or input material comprises a plurality of nucleic acid molecules at a concentration of about 1 pg or less, for example about 60 ng or less or about 5 ng to about 60 ng. For example, the starting or input material can comprise a plurality of nucleic acid molecules at a concentration of about 1 pg, about 95 ng, about 90 ng, about 85 ng, about 80 ng, about 75 ng, about 70 ng, about 65 ng, about 60 ng, about 55 ng, about 50 ng, about 45 ng, about 40 ng, about 35 ng, about 30 ng, about 25 ng, about 20 ng, about 15 ng, about 10 ng, about 9 ng, about 8 ng, about 7 ng, about 6 ng, about 5ng, or less. As a further example, the starting or input material can comprise a plurality of nucleic acid molecules at a concentration of about 5 ng to 60 ng. In some cases, the starting or input material can comprise a plurality of nucleic acid molecules at a concentration of about 5-15ng, about 10-25 ng, about 15-25 ng, about 20-30 ng, about 25-35 ng, about 30-40 ng, about 35-45 ng, about 40-50 ng, about 45-55 ng, about 50-60 ng, or about 55-65 ng. In some instances, the starting or input material comprises a plurality of nucleic acid molecules at a concentration of about 5 ng to about 30 ng.
[0049] FIG. 1A shows an exemplary method of constructing a nucleic acid library, according to some embodiments. As shown at 102 in FIG. 1A, the method comprises blunting ends of a plurality of nucleic acid molecules. Blunting can involve any reaction by which any overhangs or underhangs at the 5' and / or the 3' end of each of the nucleic acid molecules, for example dsDNA molecules, are removed, filled in, a combination of both removed and filled in, or otherwise made to be the same length.
[0050] An enzyme may be used, according to some implementations of the method, to blunt the ends of the plurality of nucleic acid molecules. This enzyme may lack 3' exonuclease activity, for example, but not limited to, any of: Taq DNA Polymerase and variants thereof (e.g., LongAmp Taq, Epimark® Taq, Hemo Klen Taq, OneTaq), Bst DNA Polymerase, Bsu DNA Polymerase, Sulfolobus DNA Polymerase IV, Klenow Fragment (3'— >5' exo-), etc. In some instances, the enzyme that blunts the ends of the plurality of nucleic acid molecules comprises 3' exonuclease activity, for example, but not limited to, any of: T4 DNA Polymerase, DNA Polymerase I, T7 DNA Polymerase, etc. In some instances, blunting the ends of the plurality of nucleic acid molecules occurs at about 15 °C to about 25 °C. For example, blunting the ends of the plurality of nucleic acid molecules can occur at about 15 °C, about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, or about 25°C.
[0051] Blunting the ends of the plurality of nucleic acid molecules can occur as a single reaction or as part of a larger reaction process (e.g., as an intermediate step). For example, blunting the ends of the plurality of nucleic acid molecules can occur as part of a larger reaction process, wherein a DNA polymerase engages in 3' end repair activity while simultaneously performing the nucleic acid tailing reaction described in process 106 below.
[0052] In some instances, blunting the ends of the plurality of nucleic acid molecules occurs in a single reaction, wherein 5' end repair and 3' end repair occurs concurrently or sequentially in the same reaction. Blunting the ends of the plurality of nucleic acid molecules can occur as a multi-step reaction process. For example, blunting the ends of the plurality of nucleic acid molecules comprises nucleic acid end repair involving 5' end repair and 3' end repair occurring as separate reactions. In these instances, 5' end repair usually involves gapfilling or cleavage of overhanging nucleotides. Typically, 3' end repair involves gap-filling.
[0053] As shown at 104 in FIG. 1A, the method comprises attaching a phosphate to 5' ends of the plurality of nucleic acid molecules. In some cases, attaching a phosphate comprises the covalent addition of a phosphate onto the 5' ends of a plurality of nucleic acid molecules by a kinase, as shown by process 104, for example by the kinase T4 Polynucleotide Kinase (PNK), wherein attaching a phosphate to 5' ends of the plurality of nucleic acid molecules can occur at about 15°C to about 25°C.
[0054] In some instances, the process at 102 and at 104 occur in the same reaction. In some instances, the processes at 102 and at 104 can occur in separate reactions. In some instances, the processes at 102 and at 104 can occur sequentially. In some instances, the processes at 102 and at 104 are separated by a nucleic acid purification process, such as any nucleic acid purification process described in the present application.
[0055] At 106, the method comprises attaching a nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules in a reaction that proceeds for less than 30 minutes. For example, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of DNA molecules can proceed for about 25 minutes or less, such as for about 1 minute to about 25 minutes. In some cases, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 15 minutes or less, such as for about 10 minutes or less. For example, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules can proceed for about 5 minutes to about 15 minutes, or for about 1 minute to about 5 minutes. In some embodiments, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes. In some cases, the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes or less.
[0056] The enzyme that adds the nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules often lacks 3' exonuclease activity, for example, but not limited to, any of Taq DNA Polymerase and variants thereof (e.g., LongAmp Taq, Epimark® Taq, Hemo Klen Taq, OneTaq), Bst DNA Polymerase, Bsu DNA Polymerase, Sulfolobus DNA Polymerase IV, Klenow Fragment (3'— >5' exo-), etc. In some instances, the enzyme that attaches the nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules is a Taq polymerase or variant thereof. The reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules can proceed at about 37 °C to about 72°C. In some cases, the enzyme that adds the nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules is the same enzyme used in process 102 and / or process 104 above. In other cases,the enzyme that adds the nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules is different from the enzyme(s) used in process 102 and / or process 104 above.
[0057] The method of attaching involves ligating of any common nucleic acid base as a nucleic acid base tail, for example deoxyadenosine (dA), deoxythymidine (dT), deoxycytosine (dC), and / or deoxy guanine (dG). For example, the nucleic acid base tail comprises dA or dT. In some instances, the nucleic acid base tail comprises dA.
[0058] In some instances, the processes at 102, at 104, and at 106 occur in the same reaction, for example concurrently. In other instances, the processes at 102, at 104, and at 106 occur in the same reaction sequentially. In some instances, the processes at 102, at 104, and at 106 occur in the same reaction that is a 2-step stepwise reaction. The first step of the 2-step stepwise reaction can comprise blunting ends of a plurality of nucleic acid molecules and attaching a phosphate to 5' ends of the plurality of nucleic acid molecules, and the second step of the 2-step stepwise reaction can comprise attaching a nucleic acid base tail to 3' ends of the plurality of DNA molecules in a reaction that proceeds for less than 30 minutes. In some instances, the first step of the 2-step stepwise reaction occurs at about 15°C to about 25°C, and the second step of the 2-step stepwise reaction occurs at about 37°C to about 72°C. In some cases, the processes at 102 and at 104 occur in the same reaction, and the process at 106 occurs in a separate reaction from processes 102 and 104. In other cases, the processes at 102 and at 106 occur in the same reaction. In some instances, the processes at 102, at 104, and at 106 each occur as a separate reaction, and those reactions can be separated by a nucleic acid purification process as described herein. In some embodiments, the processes at 102, at 104, and at 106 occur in separate sequential reactions.
[0059] At 108 of FIG. 1A, the method further includes attaching one or more sequencing adaptors to the plurality of nucleic acid molecules. In some instances, attaching the sequencing adaptors to the plurality of nucleic acid molecules comprises ligating the sequencing adaptors to the plurality of nucleic acid molecules. Furthermore, attaching sequencing adaptors to the plurality of nucleic acid molecules can comprise ligating sequencing adaptors to the plurality of nucleic acid molecules by a ligase.
[0060] Attaching the sequencing adaptors can occur directly after attaching a nucleic acid base tail to 3' ends of the plurality of DNA molecules or can occur after a nucleic acid purification process as described herein. Attaching the sequencing adaptors can occur directly after attaching a nucleic acid base tail to 3' ends of the plurality of DNA molecules.
[0061] In some instances, attaching the sequencing adaptors to the plurality of nucleic acid molecules further comprises incubating the plurality of nucleic acid molecules ligated to the sequencing adaptors with a uracil- specific excision reagent.
[0062] FIG. IB shows an exemplary embodiment of the process described in FIG. 1A. As shown at 110, the 5' and 3' ends of the dsDNA are blunted, e.g., are filled in or removed to make nucleic acid molecules with blunted ends. At 112, an enzyme (e.g., a kinase, such as T4 Polynucleotide Kinase (PNK)) capable of attaching phosphates to nucleic acids may be used to attach a phosphate group to the 5' end of the plurality of nucleic acid molecules (e.g., dsDNA duplex molecules). As shown at 114, a nucleic acid base tail, for example a deoxynucleotide (dN) tail, e.g., a dA tail, is attached to the 3' ends of the dsDNA duplex molecules. As shown in FIG. IB, processes 110, 112, and 114 occur in the same reaction using two different temperatures. Sequencing adaptors are then attached to the dsDNA duplex molecule at 116. The adaptor includes a 3' overhang that complements the tail, e.g., a 3' overhang comprising a thymidine base to complement the single nucleic acid base tail such as a dN tail, e.g., the single dA tail.
[0063] Optionally, the methods described herein can further comprise amplifying the nucleic acid molecules, for example by polymerase chain reaction (PCR). The process of amplification can add a sample index to the strands of the nucleic acid molecules. In some instances, the sequencing adaptors can include a molecular barcode, for example a molecular barcode that can be used to create a unique molecular identifier (UMI). These UMIs can allow for (e.g.) pairing the first strand (top) and the second strand (bottom) of double stranded nucleic acid duplexes. UMIs may be comprised of i) unique exogenous molecular barcodes alone that are attached to nucleic acid molecules during, e.g., ligation, ii) endogenous information within each individual nucleic acid molecule (e.g., molecular coordinates in relation to a reference genome, sequence information representing a portion of the molecule, or topological information about the molecule (such as length, methylation status, other physical characteristics)), or iii) a combination of non-unique or unique molecular barcodes and endogenous molecular information. Once the nucleic acid library is prepared, the nucleic acid molecules may be sequenced to provide sequencing reads for further downstream analyses.
[0064] Once the nucleic acid library is constructed, the nucleic acid molecules can be amplified, for example prior to sequencing. The amplifying process can allow for the attachment of a sample index to the cell-free DNA duplex. In some instances, however, a sample index is included in the sequencing adaptor, making the incorporation of a sampleindex in a downstream amplification process unnecessary. In some instances, the sequencing adaptors can include a molecular barcode, for example a molecular barcode that can be used to create a unique molecular identifier (UMI), which can allow for pairing the first strand (top) and the second strand (bottom). The amplifying can comprise performing a polymerase chain reaction (PCR) amplification technique, a non-PCR amplification technique, or an isothermal amplification technique.
[0065] The one or both strands of the nucleic acid molecule may be sequenced to generate one or more sequence reads. Sequencing may occur through any suitable process. In some implementations of the method, sequencing is performed by next-generation sequencing. “Next-generation sequencing” (or “NGS”) as used herein may also be referred to as “massively parallel sequencing” (or “MPS”) and refers to any sequencing method that determines the nucleotide sequence of either individual nucleic acid molecules (e.g., as in single molecule sequencing) or clonally expanded proxies for individual nucleic acid molecules in a high throughput fashion. Next-generation sequencing methods are described in, e.g., Metzker, M. (2010) Nature Biotechnology Reviews 11:31-46, which is incorporated herein by reference. Other examples of sequencing methods suitable for use when implementing the methods and systems disclosed herein are described in, e.g., International Patent Application Publication No. WO 2012 / 092426. The sequencing may comprise, for example, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, or direct sequencing. The sequencing may be performed using, e.g., Sanger sequencing. In some instances, the sequencing may comprise a paired-end sequencing technique that allows both ends of a fragment to be sequenced and generates high-quality, mappable sequence data for detection of, e.g., cfDNA sequences.
[0066] The first sequencing adaptor and / or the second sequencing adaptor can comprise an amplification primer binding site, a flow cell adaptor sequence, or a substrate adaptor sequence. In some instances, the sequencing comprises use of a massively parallel sequencing (MPS) technique, whole genome sequencing (WGS), whole exome sequencing, targeted sequencing, direct sequencing, or Sanger sequencing technique. Massively parallel sequencing and the massively parallel sequencing technique generally comprise next generation sequencing (NGS). In some embodiments, the sequencing is performed using a next generation sequencer, such as any of the sequencers described below.
[0067] The disclosed methods may further comprise sequencing of the nucleic acid library using sequencing platforms such as the Roche 454, Illumina Solexa, ABI-SOLiD, IONTorrent, Complete Genomics, Pacific Bioscience, Helicos, and / or the Polonator platform. Insome instances, sequencing may comprise Illumina MiSeq sequencing, Illumina HiSeq sequencing, or Illumina NovaSeq sequencing. Exemplary sequencers can include, without limitation, Roche / 454’s Genome Sequencer (GS) FLX System, Illumina / Solexa’ s Genome Analyzer (GA), Illumina’s HiSeq® 2500, HiSeq® 3000, HiSeq® 4000 and NovaSeq® 6000 Sequencing Systems, Life / APG’s Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator’s G.007 system, Helicos BioSciences’ HeliScope Gene Sequencing system, or Pacific Biosciences’ PacBio® RS system. Optimized methods for sequencing nucleic acids extracted from a sample are described in more detail in, e.g., International Patent Application Publication No. WO 2020 / 236941, the entire content of which is incorporated herein by reference.
[0068] The method can further comprise aligning the first sequence and / or the second sequence read with a reference sequence or to a sequence of a complementary strand. Complementary strands may be determined using standard molecular barcode to generate a unique molecular identifier (UMI). These UMIs may be either exogenously unique identifiers or non-unique identifiers, e.g., the exogenous barcodes added to the molecule are not unique, but after alignment, other characteristics of the molecule determined from the read, e.g., coordinates, a portion of the endogenous sequence, topological features, epigenetic features, etc., and are combined with the non-unique barcode to create a UMI. Alignment is the process of matching a query sequence read with one or more additional sequence reads or reference sequence. Alignment may further include mapping of the sequence read, for example to a location, e.g., a genomic location or locus, within a reference sequence. In some instances, a sequence read may be aligned to a known reference sequence (e.g., a wild-type sequence). In other instances, the reference sequences can be obtained from databases of the human genome (e.g., the HG19 human reference genome) or cancer mutations (e.g., COSMIC). Methods of sequence alignment for sequence reads are described in, e.g., Trapnell, C. and Salzberg, S.L. Nature Biotech., 2009, 27:455-457. Optimization of sequence alignment is described in, e.g., International Patent Application Publication No. WO 2012 / 092426. Additional description of sequence alignment methods is provided in, e.g., International Patent Application Publication No. WO 2020 / 236941, the entire content of which is incorporated herein by reference.
[0069] In some cases, the methods and systems disclosed herein may integrate the use of multiple, individually tuned, alignment methods or algorithms to optimize base-calling performance in sequencing methods, particularly in methods that rely on massively parallel sequencing (MPS). Furthermore, the disclosed methods and systems may comprise the use ofone or more global alignment algorithms and / or one or more local alignment algorithms. Examples of alignment algorithms that may be used include, but are not limited to, the Burrows-Wheeler Alignment (BWA) software bundle (see, e.g., Li, et al. (2009), “Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform”, Bioinformatics 25:1754- 60; Li, et al. (2010), Fast and Accurate Long-Read Alignment with Burrows-Wheeler Transform”, Bioinformatics epub. PMID: 20080505), the Smith-Waterman algorithm (see, e.g., Smith, et al. (1981), "Identification of Common Molecular Subsequences", J. Molecular Biology 147(1): 195-197), the Striped Smith-Waterman algorithm (see, e.g., Farrar (2007), “Striped Smith-Waterman Speeds Database Searches Six Times Over Other SIMD Implementations”, Bioinformatics 23(2): 156- 161), the Needleman-Wunsch algorithm (Needleman, et al. (1970) "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Molecular Biology 48(3):443-53), or any combination thereof.
[0070] In some instances, the methods and systems disclosed herein may also comprise the use of a sequence assembly algorithm, e.g., the Arachne sequence assembly algorithm (see, e.g., Batzoglou, et al. (2002), “ARACHNE: A Whole-Genome Shotgun Assembler”, Genome Res. 12:177-189).
[0071] The nucleic acid library from the method described herein can then be used for downstream analyses. For example, in some implementations, the constructed nucleic acid library may be used to detect the presence, likely presence, or absence of a disease, for example cancer. For example, in some implementations, the individual has a circulating tumor DNA (ctDNA) content of less than 1%, less than 0.8%, less than 0.5%, less than 0.3%, less than 0.1%, or less than 0.05%.Samples
[0072] The disclosed method may be used with any of a variety of samples (also referred to herein as specimens) comprising nucleic acids (e.g., DNA) that are collected from a subject (e.g., a patient). Examples of a sample include, but are not limited to, a liquid biopsy sample, a blood sample (e.g., a peripheral whole blood sample), a blood plasma sample, a blood serum sample, a lymph sample, a saliva sample, a sputum sample, a urine sample, a gynecological fluid sample, a circulating tumor cell (CTC) sample, a cerebral spinal fluid (CSF) sample, a pericardial fluid sample, a pleural fluid sample, an ascites (peritoneal fluid) sample, a feces (or stool) sample, or other body fluid, secretion, and / or excretion sample (orsample derived therefrom), as well as a tissue sample. In some instances, the plurality of nucleic acid molecules is obtained from a liquid biopsy sample or a tissue sample.
[0073] The sample may be collected by (e.g.) needle biopsy, fine needle aspiration, collection cup or tube, oral swab, nasal swab, vaginal swab, a cytology smear, etc.
[0074] In some instances, the sample is a liquid biopsy sample, and may comprise, e.g., whole blood, blood plasma, blood serum, buffy coat, urine, stool, sputum, saliva, or cerebrospinal fluid. In other instances, the sample may be a liquid biopsy sample and may comprise circulating tumor cells (CTCs). In some cases, the sample may be a liquid biopsy sample and may comprise cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), or any combination thereof. In some instances, the sample is a tissue sample, and may fresh frozen tissue, FFPE tissue, PBMC, tumor biopsy, organ biopsy, bone marrow aspirate, cell lines, hair follicles, or any combination thereof.
[0075] In some embodiments, the nucleic acids extracted from the sample may comprise deoxyribonucleic acid (DNA) molecules. Examples of DNA that may be suitable for analysis by the disclosed methods include, but are not limited to, genomic DNA or fragments thereof, mitochondrial DNA or fragments thereof, cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA). Cell-free DNA (cfDNA) is comprised of fragments of DNA that are released from normal and / or cancerous cells during apoptosis and necrosis and circulate in the blood stream and / or accumulate in other bodily fluids. Circulating tumor DNA (ctDNA) is comprised of fragments of DNA that are released from cancerous cells and tumors that circulate in the blood stream and / or accumulate in other bodily fluids.
[0076] In some embodiments, cell-free or circulating tumor DNA is extracted from the liquid sample. In some instances, a sample with low nucleated cellularity may require more, e.g., greater volume for DNA extraction.
[0077] The method of constructing a nucleic acid library comprises a plurality of nucleic acid molecules that is obtained from a liquid biopsy sample or a tissue sample. In some instances, the liquid biopsy sample comprises blood, plasma, buffy coat, cerebrospinal fluid, sputum, stool, urine, or saliva. The liquid biopsy sample can comprise cell-free DNA. The cell-free DNA can comprise circulating tumor DNA (ctDNA) duplex. In some instances, the tissue sample comprises fresh frozen tissue, FFPE tissue, PBMCs, tumor biopsy, organ biopsy, bone marrow aspirate, cell lines, or hair follicles.Nucleic acid extraction and processing
[0078] DNA may be extracted from liquid biopsy samples, including but not limited to blood, plasma, cerebrospinal fluid, sputum, stool, urine, or saliva or other bodily fluid samples using any of a variety of techniques presented in, e.g., Example 1 of International Patent Application Publication No. WO 2012 / 092426; Tan, et al. (2009), “DNA, RNA, and Protein Extraction: The Past and The Present”, J. Biomed. Biotech. 2009:574398; the technical literature for the Maxwell® 16 LEV Blood DNA Kit (Promega Corporation, Madison, WI); and the Maxwell 16 Buccal Swab LEV DNA Purification Kit Technical Manual (Promega Literature #TM333, January 1, 2011, Promega Corporation, Madison, WI).
[0079] A typical DNA extraction procedure, for example, comprises (i) collection of the fluid sample from which DNA is to be extracted, (ii) treatment of the fluid sample with a concentrated salt solution to precipitate proteins, lipids, and RNA, followed by centrifugation to separate out the precipitated proteins, lipids, and RNA, and (iii) purification of DNA from the supernatant to remove detergents, proteins, salts, or other reagents used during previous steps. The DNA sample optionally may be further treated with an RNase for digestion of RNA in the sample.
[0080] Examples of suitable techniques for DNA purification include, but are not limited to,(i) precipitation in ice-cold ethanol or isopropanol, followed by centrifugation (precipitation of DNA may be enhanced by increasing ionic strength, e.g., by addition of sodium acetate),(ii) phenol-chloroform extraction, followed by centrifugation to separate the aqueous phase containing the nucleic acid from the organic phase containing denatured protein, and (iii) solid phase chromatography where the nucleic acids adsorb to the solid phase (e.g., silica or other) depending on the pH and salt concentration of the buffer.
[0081] In some instances, cellular and histone proteins bound to the DNA may be removed either by adding a protease or by having precipitated the proteins with sodium or ammonium acetate, or through extraction with a phenol-chloroform mixture prior to a DNA precipitation step.
[0082] In some instances, DNA may be extracted using any of a variety of suitable commercial DNA extraction and purification kits. Examples include, but are not limited to, the QIAamp (for isolation of genomic DNA from human samples) and DNAeasy (for isolation of genomic DNA from animal or plant samples) kits from Qiagen (Germantown, MD) or the Maxwell® and ReliaPrep™ series of kits from Promega (Madison, WI).
[0083] In some instances, the disclosed methods may further comprise determining or acquiring a yield value for the nucleic acid extracted from the sample and comparing the determined value to a reference value. For example, if the determined or acquired value is less than the reference value, the nucleic acids may be amplified prior to proceeding with library construction. In some instances, the disclosed methods may further comprise determining or acquiring a value for the size (or average size) of nucleic acid fragments in the sample, and comparing the determined or acquired value to a reference value, e.g., a size (or average size) of at least 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 base pairs (bps). In some instances, one or more parameters described herein may be adjusted or selected in response to this determination.
[0084] After isolation, the nucleic acids are typically dissolved in a slightly alkaline buffer, e.g., Tris-EDTA (TE) buffer, or in ultra-pure water.EXEMPLARY EMBODIMENTS
[0085] Embodiment 1. A method of constructing a nucleic acid library, comprising: blunting ends of a plurality of nucleic acid molecules; attaching a phosphate to 5' ends of the plurality of nucleic acid molecules; attaching a nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules in a reaction that proceeds for less than 30 minutes; and attaching one or more sequencing adaptors to the plurality of nucleic acid molecules.
[0086] Embodiment 2. The method of embodiment 1, wherein blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs at about 15 °C to about 25 °C.
[0087] Embodiment 3. The method of embodiment 1 or embodiment 2, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 25 minutes or less.
[0088] Embodiment 4. The method of any one of embodiments 1-3, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 1 minute to about 25 minutes.
[0089] Embodiment 5. The method of any one of embodiments 1-4, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 15 minutes or less.
[0090] Embodiment 6. The method of any one of embodiments 1-5, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 10 minutes or less.
[0091] Embodiment 7. The method of any one of embodiments 1-5, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes to about 15 minutes.
[0092] Embodiment 8. The method of any one of embodiments 1-6, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 1 minute to about 5 minutes.
[0093] Embodiment 9. The method of any one of embodiments 1-8, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes.
[0094] Embodiment 10. The method of any one of embodiments 1-6, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 5 minutes or less.
[0095] Embodiment 11. The method of any one of embodiments 1-9, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds at about 37 °C to about 72°C.
[0096] Embodiment 12. The method of any one of embodiments 1-11, wherein the nucleic acid base tail is a deoxyadenosine tail.
[0097] Embodiment 13. The method of any one of embodiments 1-11, wherein the nucleic acid base tail is a deoxythymidine tail.
[0098] Embodiment 14. The method of any one of embodiments 1-13, wherein attaching the one or more sequencing adaptors to the plurality of nucleic acid molecules comprises ligating the one or more sequencing adaptors to the plurality of nucleic acid molecules.
[0099] Embodiment 15. The method of embodiment 14, wherein attaching the one or more sequencing adaptors to the plurality of nucleic acid molecules further comprises incubating the plurality of nucleic acid molecules ligated to the one or more sequencing adaptors with a uracil- specific excision reagent.
[0100] Embodiment 16. The method of any one of embodiments 1-15, wherein attaching one or more sequencing adaptors to the plurality of nucleic acid molecules comprises ligating the one or more sequencing adaptors to the plurality of nucleic acid molecules by a ligase.
[0101] Embodiment 17. The method of any one of embodiments 1-16, wherein blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences.
[0102] Embodiment 18. The method of any one of embodiments 1-17, wherein blunting the ends of the plurality of nucleic acid molecules comprises filling in underhang sequences.
[0103] Embodiment 19. The method of embodiment 18, wherein blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences and filling in underhang sequences in separate reactions.
[0104] Embodiment 20. The method of embodiment 18, wherein blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences and filling in underhang sequences in the same reaction.
[0105] Embodiment 21. The method of any one of embodiments 1-19, wherein blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs in the same reaction.
[0106] Embodiment 22. The method of any one of embodiments 1-19, wherein blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs in separate reactions.
[0107] Embodiment 23. The method of any one of embodiments 1-18, wherein blunting the ends of the plurality of nucleic acid molecules, attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and attaching the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules occur in the same reaction.
[0108] Embodiment 24. The method of any one of embodiments 1-22, wherein (i) blunting the ends of the plurality of nucleic acid molecules, (ii) attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and (iii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in separate reactions.
[0109] Embodiment 25. The method of any one of embodiments 1-22, wherein (i) blunting the ends of the plurality of nucleic acid molecules and (ii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in the same reaction.
[0110] Embodiment 26. The method of any one of embodiments 1-22, wherein (i) blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and (ii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in separate reactions.
[0111] Embodiment 27. The method of embodiment 26, wherein the reactions are separated by a nucleic acid purification process.
[0112] Embodiment 28. The method of any one of embodiments 1-27, wherein the plurality of nucleic acid molecules comprises 1 pg or less of the nucleic acid molecules.
[0113] Embodiment 29. The method of any one of embodiments 1-28, wherein the plurality of nucleic acid molecules comprises 60 ng or less of the nucleic acid molecules.
[0114] Embodiment 30. The method of embodiment 28 or embodiment 29, wherein the plurality of nucleic acid molecules comprises about 5 ng to 60 ng of the plurality of nucleic acid molecules.
[0115] Embodiment 31. The method of any one of embodiments 28-30, wherein the plurality of nucleic acid molecules comprises about 5 ng to about 30 ng of the plurality of nucleic acid molecules.
[0116] Embodiment 32. The method of any one of embodiments 1-31, wherein the plurality of nucleic acid molecules is obtained from a liquid biopsy sample or a tissue sample.
[0117] Embodiment 33. The method of embodiment 32, wherein the liquid biopsy sample comprises blood, plasma, buffy coat, cerebrospinal fluid, sputum, stool, urine, or saliva.
[0118] Embodiment 34. The method of embodiment 32 or embodiment 33, wherein the liquid biopsy sample comprises cell-free DNA.
[0119] Embodiment 35. The method of embodiment 34, wherein the cell-free DNA comprises circulating tumor DNA (ctDNA).
[0120] Embodiment 36. The method of embodiment 32, wherein the tissue sample comprises fresh frozen tissue, FFPE tissue, PBMCs, tumor biopsy, organ biopsy, bone marrow aspirate, cell lines, or hair follicles.
[0121] Embodiment 37. A sequencing library made according to the method of any one of embodiments 1-36.EXAMPLESExample 1: Analysis of the properties of a nucleic acid library following reduction in 3’ end tailing reaction incubation timeDesign
[0122] DNA sequencing libraries were prepared from synthetic dsDNA constructs or healthy human cfDNA isolated from blood samples using a commercially available DNA Library Preparation Kit. The kit protocol combined overhang repair, 3' end phosphorylation, and 5’ end dA tailing into one reaction that utilizes two different temperatures; adaptor ligation was a separate reaction. The combined reaction was run in a thermal cycler, with the heated lid set to > 75°C, and the following program was run: (1) 30 minutes at 20°C, followed by (2) 30minutes at 65°C. The product was then incubated for 15 min at 20°C to ligate the sequencing adaptors to the DNA molecules and then the DNA was purified.
[0123] These products were then analyzed as a baseline standard DNA sequencing library product. The DNA sequencing library product was then tested on a D1000 TapeStation (Agilent Technologies) to assess pre-PCR quantification using DNA inputs of 5-30 ng.
[0124] Samples underwent PCR amplification using KAPA PCR (DIBv2.2) and then were sequenced to analyze the unique exon coverage using 5-30 ng DNA. Results were quantified, including as coverage metrics, per target coverage metrics, and normalized coverage.
[0125] The commercially available DNA Library Preparation kit protocol was then altered by first lengthening the time of the incubation at 65°C to 45 min or to 60 min. When it was found that increasing the time of the dA tailing step, which is the reaction occurring at 65°C, led to a decrease in yield as seen on the TapeStation (see FIGS. 2A-2B and FIG. 3), the protocol was then altered to shorten the time of the 65°C incubation to test each one of the following: 1 min, 2 mins, 3 mins, 4 mins, 5 mins, and 15 mins. The DNA sequencing library product generated from each reaction was analyzed as described above, and the results for each incubation were compared, as shown below.Results
[0126] The initial hypothesis was tested that that increasing the time for all of the library construction steps (i.e., end repair, tailing, and ligation) would increase library yield and complexity (see FIGS. 1A-1B for method overview). Surprisingly, it was found that increasing the time in the nucleic acid base tailing step (e.g., dA tailing step) from the industry standard 30 mins to 45 mins or 60 mins led to a significant decrease in yield as observed by TapeStation (FIGS. 2A-2B and FIG. 3). However, upon titrating down the time from the standard 30 mins to 5 minutes (FIGS. 2A-2B) or even as low as 1 min (FIG. 3), an increase in yield was observed by TapeStation, and where 1-5 mins show similar yield.Additionally, it was repeatably observed that there was a 27.5% increase in complexity across several input masses from 8-30ng (FIGS. 4A-4B), without any observable detrimental effects, such as increased target dropouts (FIGS. 5A-5D) or GC bias (FIGS. 6A-6C).
[0127] Target dropout was assessed for the 5 min tailing reaction compared to the 30 min tailing reaction using 5-30 ng cfDNA sample input, and FIGS. 5A-5D show that at low cfDNA sample input values (i.e., at 5ng or 8ng cfDNA sample input), the per target unique coverage was slightly improved using the 5 min tailing reaction versus 30 min tailing reaction. At slightly higher sample input levels, i.e., at 15ng or 30ng cfDNA sample input, theper target unique coverage was significantly improved using the 5 min tailing reaction versus 30 min tailing reaction.
[0128] The percent of GC content was assessed for GC content bias using a 5 min tailing reaction compared to 30 min tailing reaction using 5ng, 8ng, or 15 ng cfDNA sample input. FIGS. 6A-6C show that the percent GC content closely aligned across the 5 min and 30 min tailing reactions at 8ng and 15ng cfDNA sample input. A slight increase in normalized coverage was seen around 80-100% GC content using the 5 min tailing reaction versus 30 min tailing reaction.
[0129] The data show an increase in the number of molecules that are retained in double stranded library construction as a result of controlling the dA tailing reaction in the described library construction methods that include a tailing step. This increase in efficiency is measured as an increase in library yield and an increase in unique molecules that are sequenced (i.e., library complexity). More specifically, decreasing the dA tailing time significantly increases library complexity by 27.5% across input masses between 8-30ng in the context of double stranded library preparation. Thus, the method described herein permits a decrease in the sample input mass and an increase in library complexity, which is particularly valuable for analysis of samples that have low nucleic acid concentration.
[0130] It should be understood from the foregoing that, while particular implementations of the disclosed methods have been illustrated and described, various modifications can be made thereto and are contemplated herein. It is also not intended that the invention be limited by the specific examples provided within the specification. While the invention has been described with reference to the aforementioned specification, the descriptions and illustrations of the preferable embodiments herein are not meant to be construed in a limiting sense. Furthermore, it shall be understood that all aspects of the invention are not limited to the specific depictions, configurations or relative proportions set forth herein which depend upon a variety of conditions and variables. Various modifications in form and detail of the embodiments of the invention will be apparent to a person skilled in the art. It is therefore contemplated that the invention shall also cover any such modifications, variations and equivalents.
Claims
CLAIMSWhat is claimed is:
1. A method of constructing a nucleic acid library, comprising: blunting ends of a plurality of nucleic acid molecules; attaching a phosphate to 5' ends of the plurality of nucleic acid molecules; attaching a nucleic acid base tail to 3' ends of the plurality of nucleic acid molecules in a reaction that proceeds for less than 30 minutes; and attaching one or more sequencing adaptors to the plurality of nucleic acid molecules.
2. The method of claim 1, wherein blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs at about 15 °C to about 25 °C.
3. The method of claim 1 or claim 2, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for 25 minutes or less.
4. The method of claim 1, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 1 minute to about 25 minutes.
5. The method of claim 1, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds for about 5 minutes.
6. The method of claim 1, wherein the reaction that attaches the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules proceeds at about 37°C to about 72°C.
7. The method of claim 1, wherein the nucleic acid base tail is a deoxyadenosine tail or a deoxy thymidine tail.
8. The method of claim 1, wherein attaching the one or more sequencing adaptors to the plurality of nucleic acid molecules comprises ligating the one or more sequencing adaptors to the plurality of nucleic acid molecules.
9. The method of claim 8, wherein attaching the one or more sequencing adaptors to the plurality of nucleic acid molecules further comprises incubating the plurality of nucleic acid molecules ligated to the one or more sequencing adaptors with a uracil- specific excision reagent.
10. The method of claim 1, wherein blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences and / or filling in underhang sequences.
11. The method of claim 10, wherein blunting the ends of the plurality of nucleic acid molecules comprises removing overhang sequences and filling in underhang sequences in the same reaction.
12. The method of claim 1, wherein blunting the ends of the plurality of nucleic acid molecules and attaching the phosphate to 5' ends of the plurality of nucleic acid molecules occurs in the same reaction.
13. The method of claim 1, wherein blunting the ends of the plurality of nucleic acid molecules, attaching the phosphate to the 5' ends of the plurality of nucleic acid molecules, and attaching the nucleic acid base tail to the 3' ends of the plurality of nucleic acid molecules occur in the same reaction.
14. The method of claim 1, wherein (i) blunting the ends of the plurality of nucleic acid molecules and (ii) attaching the nucleic acid base tail to the 3' ends of a plurality of nucleic acid molecules occur in the same reaction.
15. The method of claim 1, wherein the plurality of nucleic acid molecules comprises 60 ng or less of the nucleic acid molecules.
16. The method of claim 15, wherein the plurality of nucleic acid molecules comprises about 5 ng to 60 ng of the plurality of nucleic acid molecules.
17. The method of claim 1, wherein the plurality of nucleic acid molecules is obtained from a liquid biopsy sample or a tissue sample.
18. The method of claim 17, wherein the liquid biopsy sample comprises cell-free DNA.
19. The method of claim 18, wherein the cell-free DNA comprises circulating tumor DNA (ctDNA).
20. A sequencing library made according to the method of claim 1.
Citation Information
Patent Citations
Detecting and classifying copy number variation
US20130029852A1
Method for identifying DNA base editing by means of cytosine deaminase
US20200131536A1
